Enteric polymers are widely used in amorphous solid dispersion (ASD) formulations. The
aim of the current study was to explore ASD failure mechanisms across a wide range of pH …

Recent work has highlighted that amorphous solid dispersions (ASDs) containing
delamanid (DLM) and an enteric polymer, hypromellose phthalate (HPMCP), appear to be …

Understanding the dissolution mechanisms of amorphous solid dispersions (ASDs) and
being able to link enhanced drug exposure with process parameters are key when …

Amorphous solid dispersions (ASDs) are a well-documented formulation approach to
improve the rate and extent of dissolution for hydrophobic pharmaceuticals. However …

Several drugs are pH-dependent soluble weak bases with a poor solubility in the intestinal
pH range. Additionally a variable gastric pH, which is a common issue in the population …

Weakly acidic polymers, historically used as enteric coatings, are increasingly being
employed in solubility-enhancing amorphous solid dispersion (ASD) formulations. However …

To reduce the pill burden associated with amorphous solid dispersions (ASDs), which arises
from the large quantity of polymer used in the formulation, it is of interest to understand the …

Amorphous solid dispersions (ASD) are increasingly used to improve the oral bioavailability
of poorly water-soluble compounds. However, hydrophilic polymers in ASD have high water …

Oral delivery of poorly water-soluble, weakly basic drugs may be problematic based on the
drugs' intrinsic properties. Many drugs in this subset have overcome barriers to delivery …

The poor aqueous solubility of many active pharmaceutical ingredients (APIs) dominates
much of the early drug development portfolio and poses a major challenge in …